Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

80.39 -2.71 (-3.26%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 08, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

May 07, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

May 07, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Analyst Ratings For Mirum Pharmaceuticals ↗

April 17, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals ↗

March 18, 2024

Via Benzinga

Critical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To Know ↗

February 29, 2024

Via Benzinga

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

May 01, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 10, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

April 02, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals: Q4 Earnings Insights ↗

February 28, 2024

Via Benzinga

Preview: Mirum Pharmaceuticals's Earnings ↗

February 27, 2024

Via Benzinga

Where Mirum Pharmaceuticals Stands With Analysts ↗

January 11, 2024

Via Benzinga

$5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying ↗

March 28, 2024

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

Via Benzinga

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

March 25, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy ↗

March 14, 2024

FDA approves Livmarli by Mirum Pharmaceuticals for cholestatic pruritus in PFIC patients ≥5 years old. Data from Phase 3 MARCH study. Analysts bullish on broader coverage in 2024, with price target...

Via Benzinga

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

March 13, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

The Latest Analyst Ratings For Mirum Pharmaceuticals ↗

December 19, 2023

Via Benzinga

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 08, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

March 05, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI

February 29, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

February 28, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024

February 21, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 09, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 19, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

January 16, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 10, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday ↗

January 10, 2024

U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session.

Via Benzinga

Topics Stocks

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

January 08, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Mirum Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.